Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

por Talpaz, M, Hehlmann, R, Quintás-Cardama, A, Mercer, J, Cortes, J
Publicado 2013

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

por Hughes, T P, Saglio, G, Quintás-Cardama, A, Mauro, M J, Kim, D-W, Lipton, J H, Bradley-Garelik, M B, Ukropec, J, Hochhaus, A
Publicado 2015

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL

por Lee, H J, Gallardo, M, Ma, H, Zhang, X, Larsson, C A, Mejia, A, Hornbaker, M J, Qi, Y, Su, X, Pageon, L R, Quintas-Cardama, A, Post, S M
Publicado 2016